P046: Occurrence of anaphylaxis in adult incident pegvaliase-treated PKU patients in a post-marketing safety analysis in the United States

patients aged 12-17, 18-29, and 30+, respectively).Correspondingly, the proportion of adult patients with blood Phe levels >1200 mol/L has declined (from 15% to 6.0% and 20% to 7.4% in patients aged 18-29 and 30+ years, respectively).The improvements in blood Phe levels in the adult PKU population may be, at least in part, explained by increased awareness of the need for lifelong treatment as well as the availability of pegvaliase in this age group.